Expert Insights On Upstream Bioprocessing

  1. Forum Notebook: Quick Takes From USP's mRNA Virtual Summit 5/1/2024

    The United States Pharmacopeia held a forum in February to exchange ideas about analytical methodologies and release testing. Here's a recap of the event.

  2. SUS, PAT, And Other Tech Advancing Upstream Bioprocessing 4/26/2024

    As the sector grows, technology and techniques are becoming more sophisticated, including single-use systems, automation, and bioreactors.

  3. NK Cell Therapies: How Artiva Biotherapeutics Leverages Its "Manufacturing First" Approach 4/24/2024

    We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

  4. Improving Governance And Compliance With Knowledge Management 4/23/2024

    Knowledge management — it’s not just a soulless exercise. In the last part of his series, Hirsh helps bridge the gap between compliance and business needs.

  5. Cell Counting Is Growing More Important Amid Advanced Therapy's Rise 4/12/2024

    You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.

  6. How Continuous Bioprocessing Is Shaping Modern Biopharma Manufacturing 3/28/2024

    Continuous processing adoption so far has been slow; however, market research shows demand and capacity will grow significantly over the next four years.

  7. How To Measure Cell Density In Real Time With Soft Sensors 3/21/2024

    Soft sensors can enable real-time monitoring of key process variables, including viable cell density. Here's how one team at Takeda put them to use.

  8. How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing 2/27/2024

    To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts. 

  9. Continuous Manufacturing: Many Want It, But Here's Why Few Have It 2/13/2024

    In 2023, biomanufacturers showed an increasing interest in continuous manufacturing, but uptake, believe it or not, slowed down. Let’s explore the reasons why with data from BioPlan Associates.

  10. It's Time To Dethrone CHO When It Comes To mAb Production 2/1/2024

    Let’s be honest — CHO is an expensive, inefficient, and pervasive way to make mAbs. Emerging and evolving alternatives discussed here include microbial systems, which tend toward better efficiency.